2019 BCOP Education


Check out the latest edition of HOPA News!


Latest Discussions

HOPA Bulletin

  • For people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), results from a new study suggest that using whole-genome sequencing to identify the genomic changes in their tumor cells could simplify and improve how doctors select the best treatment regimen for each patient. Whole-genome sequencing can determine the complete genetic makeup of a patient's sample in a single test, whereas the current approach to identify genomic changes involves several different tests.

Getting Started

Check out our user guide for further information.

Connect With Us